Publication
Title
Pemetrexed in thoracic cancer
Author
Abstract
Both lung cancer and mesothelioma are malignancies with increasing incidence, and both are primarily due to inhalation of an external carcinogen. The occurence of both diseases is expected to rise worldwide, although a stabilisation and/or decrease may be anticipated in some developed countries. There are other common similarities to both cancers, including the median age of their patients, the advanced stage at presentation, the outcome and the treatments given. This review focuses on the available evidence of a novel antifolate agent, pemetrexed, in the treatment of both of these thoracic malignancies. Current status, persisting controversies and future developments are discussed.
Language
English
Source (journal)
Expert opinion on pharmacotherapy. - London
Publication
London : 2006
ISSN
1465-6566
Volume/pages
7:7(2006), p. 917-928
ISI
000237505500008
Full text (Publisher's DOI)
UAntwerpen
Faculty/Department
[E?say:metaLocaldata.cgzprojectinf]
Publication type
Subject
External links
Web of Science
Record
Identification
Creation 18.11.2014
Last edited 05.11.2017